MORE►
biotech funding
R.A. Session II
Success in the Genes: Launching in a Pandemic Didn’t Hurt This Fast-Growth Dallas Biotech Company
by Quincy Preston | Feb 26, 2021
In under six months, Taysha Gene Therapies rocketed from the unveiling of its UTSW spinout to a $157 million initial public offering. We talk with Founder and CEO R.A. Session II about the biotech with big plans.
by Quincy Preston and Sandra Engelland |
Feb 11, 2021
Here are 32 North Texas startups that successfully pulled in capital to back their ventures.
Fitting the digital demands of a global pandemic, it's a tech-heavy group, with liberal doses of biotech and healthcare-related firms.
MORE►
by Alex Edwards |
Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
